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ABSTRACT
Cell cycle and apoptosis regulator 2 (CCAR2, formerly known as DBC1) is a nuclear 
protein largely involved in DNA damage response, apoptosis, metabolism, chromatin 
structure and transcription regulation. Upon DNA lesions, CCAR2 is phosphorylated 
by the apical kinases ATM/ATR and this phosphorylation enhances CCAR2 binding to 
SIRT1, leading to SIRT1 inhibition, p53 acetylation and p53-dependent apoptosis. 
Recently, we found that also the checkpoint kinase Chk2 and the proteasome activator 
REGγ are required for efficient CCAR2-mediated inhibition of SIRT1 and induction of 
p53-dependent apoptosis.
Here, we report that CCAR2 is required for the repair of heterochromatic DNA 
lesions, as cells knock-out for CCAR2 retain, at late time-points after genotoxic 
treatment, abnormal levels of DNA damage-associated nuclear foci, whose timely 
resolution is reinstated by HP1β depletion. Conversely, repair of DNA damages in 
euchromatin are not affected by CCAR2 absence. 
We also report that the impairment in heterochromatic DNA repair is caused by 
defective Chk2 activation, detectable in CCAR2 ablated cells, which finally impacts on 
the phosphorylation of the Chk2 substrate KAP1 that is required for the induction of 
heterochromatin relaxation and DNA repair.
These studies further extend and confirm the role of CCAR2 in the DNA damage 
response and DNA repair and illustrate a new mechanism of Chk2 activity regulation. 
Moreover, the involvement of CCAR2 in the repair of heterochromatic DNA breaks 
suggests a new role for this protein in the maintenance of chromosomal stability, 
which is necessary to prevent cancer formation.
INTRODUCTION
Human CCAR2 (cell cycle and apoptosis 
regulator 2, also known as DBC1 or KIAA1967) is a 
nuclear protein involved in several biological processes, 
such as DNA damage response (DDR) and apoptosis, 
cellular metabolism, epigenetics, cell proliferation and 
tumorigenesis, nuclear receptor function, circadian cycle 
and mRNA splicing [1]. Upon DNA damage, the apical 
checkpoint kinases ATM and ATR phosphorylate CCAR2 
on T454, enhancing its inhibitory binding to the histone 
deacetylase SIRT1, promoting p53 acetylation and p53-
dependent apoptosis [2, 3]. Besides phosphorylation, 
other CCAR2 post-translational modifications like 
acetylation and sumoylation finely regulate SIRT1 activity 
[4-6]. Additionally, the checkpoint kinase Chk2 and the 
proteasome activator REGγ do also play a role in the 
regulation of SIRT1 by CCAR2, as we recently reported 
[7].
Chk2 is a downstream component of the DDR 
[8], activated in response to DSBs by ATM, which 
phosphorylates Chk2 on T68, triggering its dimerization, 
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auto-phosphorylation and activation. Chk2 phosphorylates 
several substrates, among which p53, Brca1, Cdc25C, 
PML, TRF2, KAP1 and REGγ, amplifying the DDR 
signaling and promoting cell cycle delay, DNA repair or 
apoptosis [7, 8].
Besides SIRT1, CCAR2 inhibits the activity of the 
histone-modifying enzymes SUV39H1 and HDAC3 [9, 
10], thus playing an important role in chromatin structure 
regulation. 
Chromatin relaxation is a key event in DDR as it 
favors the recruitment of repair factors at damaged sites. 
It is now well established that DNA lesions located in 
the tightly packaged heterochromatin are repaired with a 
slower kinetics compared to those occurring in the less 
compact and transcriptionally active euchromatin [11, 
12]. Many proteins are involved in the regulation of 
chromatin structure; among them, the transcriptional co-
repressor KAP1 (KRAB domain-associated protein 1) 
recruits histone deacetylases and methyltransferases to 
promote the transcriptionally inactive state of chromatin 
[13, 14]. Moreover, KAP1, which is also known to 
associate with CCAR2 [15], is involved in the recruitment 
of the heterochromatin protein 1 family (HP1α, HP1β e 
HP1γ) that binds methylated histones, preserving their 
methylation and promoting gene silencing [14, 16]. 
However, upon DNA damage KAP1 is phosphorylated 
by ATM on S824 [17] and by Chk2 on S473 [18, 19] 
inducing chromatin relaxation and DNA repair in 
the heterochromatic regions of the genome. Of note, 
phosphorylation of S473 by Chk2 decreases the interaction 
between KAP1 and HP1 proteins and is necessary for 
HP1β mobilization, a key event for DNA repair in the 
heterochromatin [18-21].
Here we report that, in human cells, CCAR2 
loss markedly impairs the repair of DNA lesions in 
heterochromatin as consequence of a reduced kinase 
activity of Chk2 towards KAP1.
RESULTS
CCAR2 is required for the repair of DNA lesions
To thoroughly investigate the role of CCAR2 in the 
repair of DNA breaks, we generated U2OS cells knock-
out for CCAR2 (CCAR2-/-) using the CRISPR/Cas9 
system [22]. For our studies, we initially selected a U2OS 
clone characterized by the insertion of a single nucleotide 
in both strands of CCAR2 gene (alignment is shown in 
Supplementary Figure 1A and sequence chromatogram 
in Supplementary Figure 1B), which caused a premature 
stop codon formation and complete loss of CCAR2 protein 
expression. The absence of CCAR2 was further confirmed 
by immunofluorescence analyses performed with two 
different anti-CCAR2 antibodies recognizing epitopes 
at the N-terminus (Supplementary Figure 1C, right) and 
C-terminus (Supplementary Figure 1C, left), and by 
western blot (Supplementary Figure 1D). 
Next, we assessed in these cells the repair of 
DNA damages induced by etoposide treatment, a 
chemotherapeutic drug that inhibits topoisomerase II, 
finally inducing double strand breaks (DSBs), and that 
is known to strongly promote ATM/ATR-dependent 
phosphorylation of CCAR2 and apoptosis [2]. Although 
etoposide is known to induce DNA lesions mainly in 
S-G2 phases of the cell cycle, we found that, at the dose 
we used (20µM), etoposide can induce DSBs in all cells. 
Indeed immunofluorescence staining with the DSBs 
marker γH2AX demonstrated that all cells are damaged 
1h after etoposide treatment, as previously reported [23, 
24], and these lesions are partially repaired 24h later 
(Supplementary Figure 2).
 Repair of DNA breaks is bimodal, with those in 
euchromatin being repaired within few hours following 
damage and those in heterochromatin much later, 
necessitating chromatin relaxation for repair [11]. As 
CCAR2 appears involved in chromatin dynamics through 
its repression of the histone modifying enzymes SIRT1, 
SUV39H1, HDAC3 and interaction with KAP1 [2, 3, 
9, 10, 15], we especially investigated the late repair of 
DNA lesions which critically depends on chromatin 
remodeling functionality. Specifically, we analyzed by 
immunofluorescence (IF) the formation and clearance of 
γH2AX and 53BP1 nuclear foci, two biomarkers of DSBs 
[25], in U2OS CCAR2+/+ and CCAR2-/- cells treated 
with etoposide for 1h, and then incubated in drug-free 
medium for 24h as previously reported [18]. Although 
no differences were found in the levels of DSBs at 1-3h 
after treatment, since 53BP1 foci and γH2AX levels were 
similar in CCAR2+/+ and CCAR2-/- cells (Supplementary 
Figure 3A and 3B), the 53BP1 and γH2AX staining, at 
24h, revealed three subsets of nuclei exhibiting either 
large numbers of foci (>60), less than 60 foci, or no foci 
(Figure 1A, Supplementary Figure 2 and 3A). Notably, 
however, immunostaining of γH2AX (Figure 1B) and 
53BP1 (Figure 1C) revealed that both the fraction of cells 
containing >60 foci and the overall number of foci in the 
remaining cells were markedly higher in CCAR2-/- than in 
CCAR2+/+ cells and similar results were also obtained by 
staining of 53BP1 in U2OS cells transfected with control 
or CCAR2 siRNA (Figure 1D and Supplementary Figure 
3C), thus excluding a clone specific effect. In accordance 
with these data, the percentage of cells with repaired 
DNA lesions (less than 5 foci) is strongly reduced in 
CCAR2-/- compared to CCAR2+/+ cells, as evident from 
the chart showing foci number versus cells distribution 
(Supplementary Figure 3D). 
Moreover, the role of CCAR2 in the repair of DSBs 
was further confirmed in time course analyses of 53BP1 
foci in etoposide treated BJ-hTERT human fibroblast cells 
where CCAR2 gene was knocked-out by the CRISPR/
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Figure 1: Cells negative for CCAR2 have defective DNA repair. A. Examples of 53BP1 IF staining in U2OS cells before and 24h 
after etoposide exposure. B. Charts depicting the percentage of cells with >60 γH2AX foci in U2OS CCAR2+/+ and CCAR2-/- cells 24h 
after etoposide exposure (left) and the average number of γH2AX foci detected in CCAR2+/+ and CCAR2-/- cells with less than 60 foci 
before and 24h after etoposide treatment (right). C. Charts obtained as in B, but with 53BP1 staining D. Charts depicting the percentage of 
cells with >60 53BP1 foci in U2OS siLUC and siCCAR2 cells 24h after etoposide exposure (left) and the average number of 53BP1 foci 
detected in cells with less than 60 foci before and 24h after etoposide treatment (right). Results are the mean and standard deviation of at 
least 3 independent experiments. p values indicate statistically significant differences.
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Cas9 system (Supplementary Figure 3E). Analysis of a 
BJ-hTERT-CCAR2-/- clone revealed that this protein 
is required for efficient repair of DSBs, after genotoxic 
treatment and, thus, this CCAR2 function is not restricted 
to cancer cells.
To investigate if accumulation of cells with 
unrepaired DNA breaks in CCAR2 ablated cells could 
be due to alterations of cell cycle progression induced by 
CCAR2 absence, we performed FACS analyses [26] of 
U2OS CCAR2+/+ and CCAR2-/- cells, before and after 
damage, and found similar cell cycle profile in both cell 
lines (Supplementary Figure 4). 
To deepen investigate this point, we studied 
S-phase progression and G2/M transition of CCAR2+/+ 
and CCAR2-/- cells. For this, cells treated with 
etoposide for 1h, were released respectively in EdU or 
nocodazole containing medium and then EdU positive 
cells (corresponding to S-phase progressing cells; 
Figure 2A) and phospho-Histone-H3 (Ser10) positive 
cells (corresponding to mitotic cells; Figure 2B) were 
enumerated [26]. As shown in the charts, no significant 
differences between CCAR2+/+ and CCAR2-/- cells 
were found, thus suggesting that the DNA repair defect 
observed in CCAR2 depleted cells is not due to defects in 
checkpoint activation. In addition, findings that cells with 
persistent DNA damage induced foci can be both cyclin 
B1 positive or negative (a marker of G2 cells, Figure 2C) 
further confirm that damaged cells are not in a specific cell 
cycle phase. 
Finally, to verify if CCAR2 could be involved in 
the repair of DNA lesions caused by genotoxic agents 
different from etoposide and capable to induce DSBs in all 
cell cycle phases, we exposed CCAR2+/+ and CCAR2-/- 
cells to ionizing radiation (IR). Staining and enumeration 
of 53BP1 foci in these cells revealed that CCAR2 ablation 
prevents the correct repair of DSBs also in response to IR 
(Figure 2D).
Since SIRT1 is the main CCAR2 target in the DNA 
damage response, we verified whether this protein could 
have some role in CCAR2 mediated DNA repair. For this 
CCAR2+/+ and CCAR2-/- cells were transfected with 
control or SIRT1 siRNAs and 53BP1 foci were analysed 
in response to etoposide treatment. However no significant 
differences were found between control and SIRT1 
depleted cells (Figure 2E and Supplementary Figure 5A). 
Altogether these results suggest that CCAR2 is 
required for the repair of DSBs in both normal and cancer 
cells and that this CCAR2 function is cell cycle and SIRT1 
independent. 
CCAR2 is involved in heterochromatic DNA 
repair
Since CCAR2 seems to be involved in chromatin 
remodelling and these events are particularly important 
for the repair of heterochromatic DNA lesions which 
requires chromatin relaxation, we investigated if the foci 
retained in CCAR2 negative and depleted cells correspond 
to heterochromatic DSBs. It was previously demonstrated 
that depletion of proteins of the HP1 family can alleviate 
the defects in the repair of heterochromatic DSBs [19]; 
particularly HP1β mobilization seems to be a key event 
for the reorganization of chromatin structure and repair 
of DNA breaks in the heterochromatin [18, 19]. Thus, 
to verify if CCAR2 depletion affects the repair of DNA 
breaks in heterochromatin, we depleted HP1β by siRNA 
in U2OS CCAR2+/+ and CCAR2-/- cells and enumerated 
53BP1 foci 24h after etoposide treatment. Significantly, 
HP1β ablation rescued the DNA repair defect of etoposide-
treated CCAR2-/- cells (Figure 3A and Supplementary 
Figure 5B and 5C). Then, to further confirm that the late 
53BP1 foci detectable in CCAR2 null cells correspond to 
heterochromatic DNA lesions, we analysed the levels of 
the heterochromatic marker H3K9me3 associated with 
53BP1 positive polynucleosomes. As shown in Figure 
3B, the amount of 53BP1 co-precipitating with H3K9me3 
strongly increased after damage in U2OS CCAR2-/- 
compared to CCAR2+/+ cells. 
To further confirm that the DNA repair defect 
detectable in CCAR2 ablated cells could be ascribed to 
impairment in the repair of heterochromatic DSBs, we 
took advantage of U2OS AID-DIvA cells [27]. These cells 
are characterized by the inducible nuclear translocation of 
the AID-AsiSI enzyme, which is able to cut the genome 
at known sites, but only in the euchromatic regions, and 
that can be turned off by auxin addition. AID-DIvA cells 
were transfected with control or CCAR2 siRNA and the 
induction and repair of DNA lesions followed by 53BP1 
staining. Foci were enumerated and the data reported in 
the chart clearly demonstrate that there are no significant 
differences between control and CCAR2 depleted cells and 
thus CCAR2 is not involved in the repair of euchromatic 
DNA breaks (Figure 3C and Supplementary Figure 6).
Collectively, these data indicate that CCAR2 
is required for the repair of DSBs localized in the 
heterochromatic regions of the genome.
CCAR2 regulates Chk2 activity towards KAP1
As CCAR2 is known to interact with ATM [3], a 
kinase also required for heterochromatic DNA repair [17, 
20], we first checked the impact of CCAR2 overexpression 
on ATM activity. For this, etoposide-treated U2OS-
CCAR2+/+ and CCAR2-/- cells were harvested 6h later 
and analysed for the phosphorylation of the ATM targets 
Chk2 and KAP1. However, neither the phosphorylation 
of Chk2-T68 nor that of KAP1-S824 was influenced by 
CCAR2 overexpression, a finding consistent with the 
autophosphorylation of ATM-S1981, which is unaffected 
by CCAR2 (Supplementary Figure 7). 
We previously reported that Chk2, like ATM, 
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Figure 2: The DNA repair defect of CCAR2 negative cells is not cell cycle dependent. A. U2OS CCAR2+/+ and CCAR2-
/- cells were treated with etoposide for 1h and released in EdU containing medium for 4h. EdU positive cells were stained, enumerated 
and obtained data were reported in the chart. B. U2OS CCAR2+/+ and CCAR2-/- cells were treated with etoposide for 1h and released in 
nocodazole containing medium for 24h to trap mitotic cells. Obtained results were reported in the chart. No significant differences between 
CCAR2+/+ and CCAR2-/- cells were detected in S phase progression nor in G2/M transition. C. Examples of cyclin B1 and 53BP1 double 
immunostaining. D. Charts depicting the percentage of cells with >60 foci in U2OS CCAR2+/+ and CCAR2-/- cells 24h after IR exposure 
(left) and the average number of 53BP1 foci detected in CCAR2+/+ and CCAR2-/- cells with less than 60 foci before and 24h after IR 
treatment (right). E. Charts depicting the percentage of cells with more than 60 foci (left) and the average number of foci in the remaining 
cells (right) in CCAR2+/+ and CCAR2-/- cells silenced or not for SIRT1. NS, not significant difference (p = 0.1).
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interacts with CCAR2 [7]. As Chk2 phosphorylation 
of KAP1-S473 induces the mobilization of HP1 from 
heterochromatin and promotes chromatin relaxation 
[18, 19], we investigated whether the defects in 
heterochromatic DNA repair in CCAR2-deficient 
cells was somewhat linked to Chk2. To this aim, we 
initially analyzed Chk2 autophosphorylation on T387 
in CCAR2+/+ and CCAR2-/- U2OS cells, and, quite 
surprisingly, found a reduced Chk2-pT387 signal in the 
latter cells at 6h of etoposide treatment (Figure 4A). 
Conversely, the expression of CCAR2WT led to a twofold 
increase in Chk2-pT387 signal, and almost a similar 
increase was seen by the expression of CCAR2T454A 
phosphomutant [2] (Figure 4B), clearly indicating 
that, in human cells, CCAR2 positively regulates Chk2 
autophosphorylation. 
Next, we analyzed the time-dependent KAP1-S473 
phosphorylation after etoposide treatment. As shown 
in Figure 4C, the absence of CCAR2 reduced the 
phosphorylation of KAP1-S473 and similar results 
were obtained also in BJ-hTERT-CCAR2-/- cells 
(Supplementary Figure 8) and after CCAR2 silencing and 
in response to IR (data not shown), further confirming 
that CCAR2 regulates Chk2 activity towards KAP1. 
To verify the specificity of these events, we transfected 
U2OS-CCAR2-/- cells with vectors encoding CCAR2WT, 
CCAR2T454A, FLAG-Chk2WT and FLAG-Chk2KD (kinase 
dead, a catalytically inactive mutant) and, after etoposide 
Figure 3: CCAR2 is involved in heterochromatic DNA repair. A. Charts depicting the percentage of cells with more than 60 
foci (left) and the average number of foci in the remaining cells (right) in CCAR2+/+ and CCAR2-/- cells silenced or not for HP1β. 
B. Coimmunoprecipitation analysis of 53BP1 and H3K9me3 in U2OS-CCAR2+/+ and CCAR2-/- cells before and after etoposide 
treatment; right panel: input. C. Analysis of 53BP1 foci in AID-DIvA cells transfected with control or CCAR2 siRNA in response to 
4-hydroxytamoxifen (4-OHT) and auxin (IAA) treatments for the indicated time points.
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Figure 4: CCAR2 is required for Chk2 activation. Chk2 immunoprecipitates from CCAR2+/+ and CCAR2-/- U2OS cells A., or 
from CCAR2WT and CCAR2T454A overexpressing cells B. were analyzed for Chk2-T387 autophosphorylation before and after etoposide 
exposure. C. Time course analysis of KAP1-S473 phosphorylation in CCAR2+/+ and CCAR2-/- cells exposed to etoposide. D. KAP1-S473 
phosphorylation in CCAR2-/- cells transfected with WT or KD Chk2 or CCAR2WT and CCAR2T454A encoding vectors and treated with 
etoposide for 6h. E. Time course analysis of KAP1-S473 phosphorylation in etoposide treated CCAR2-overexpressing cells. Arrow 
indicates CCAR2 specific band. F. Phosphorylation of KAP1-S473 in CCAR2-overexpressing cells treated or not with etoposide and 
VRX0466617. Accumulation of Chk2-pT68 demonstrates VRX0466617 efficacy [28]. G. Association of KAP1 and HP1α in CCAR2+/+ 
and CCAR2-/- cells before and 24h after etoposide treatment for 1h (left). PC: pre-cleared negative control. Right panel: input. 
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treatment, we found that expression of CCAR2 (both the 
wild type and, to a lesser extent, the T454A mutant) and 
wild type Chk2 restores KAP1-S473 phosphorylation, but 
not the expression of Chk2KD (Figure 4D), indicating that 
the defective KAP1 phosphorylation on S473 is caused 
by CCAR2 deficiency which in turn affects Chk2 activity. 
Moreover, in accordance with these data we found 
that the overexpression of CCAR2 in U2OS cells resulted 
in increased KAP1-S473 phosphorylation (Figure 4E) at 
all time points after etoposide treatment, and this event 
was Chk2-dependent as it was abrogated by pre-treatment 
of cells with the Chk2-specific inhibitor VRX0466617 
[28] (Figure 4F). 
Since KAP1 phosphorylation on S473 regulates 
its interaction with HP1 family members [18], we 
investigated this association in relation to CCAR2 
expression. For this, CCAR2+/+ and CCAR2-/- U2OS 
cells were transfected with FLAG-HP1α and analyzed by 
immunoprecipitation for KAP1-HP1α interaction before 
and after etoposide treatment. While in U2OS-CCAR2+/+ 
cells etoposide treatment led to a reduced KAP1-HP1α 
binding, in accordance with previous reports [18], this 
treatment markedly enhanced the KAP1-HP1α association 
in CCAR2-/- cells (Figure 4G), an increase which could 
be explained by the defective KAP1 phosphorylation that 
prevents its dissociation from HP1α. 
These findings further confirm the importance of 
CCAR2 in chromatin dynamics following DNA damage 
and that the DNA repair defect of CCAR2 knock-out 
cells can be ascribed to a defective Chk2 functionality 
on KAP1. Given however that CCAR2 silencing does 
not affect the proapoptotic function of Chk2 [7], a 
finding further substantiated here in CCAR2-/- cells 
(Supplementary Figure 9A), nor the phosphorylation of 
p53 on S20 [8] (Supplementary Figure 9B), it is likely that 
CCAR2 might differentially regulate the activity of Chk2 
towards distinct targets. 
The CCAR2-dependent failure of DNA repair is 
caused by defective Chk2 activity
We reasoned that if Chk2 is involved in CCAR2-
dependent repair of heterochromatic DSBs, its depletion 
might predictably result in a similar repair defect as 
CCAR2 deficiency, and furthermore if Chk2 and CCAR2 
work epistatically, then ablation of both proteins should 
not have an additive effect. To test this hypothesis U2OS 
CCAR2+/+ and CCAR2-/- cells were transfected with 
control or Chk2 siRNA and 53BP1 foci enumerated 
before and after etoposide treatment. As reported in the 
graphs (Figure 5A and Supplementary Figure 10), Chk2 
knockdown, in CCAR2+/+ cells, induced a significant 
accumulation of cells with >60 foci and an increase in 
the average number of foci in the remaining cells, but 
this effect was not additive with that induced by CCAR2 
ablation. Hence, Chk2 and CCAR2 appear to function in 
the same pathway to regulate the repair of heterochromatic 
DNA lesions. 
To further verify that the DNA repair deficiency of 
CCAR2-/- cells is indeed due to defective Chk2 activity, 
53BP1 foci were assessed 24h after etoposide treatment in 
U2OS-CCAR2-/- cells transfected with Chk2WT or Chk2KD 
vectors and, as shown in Figure 5B-5C, cells expressing 
Chk2WT had fewer 53BP1 foci than mock or Chk2KD 
expressing cells, indicating that increased Chk2 activity 
can rescue the repair defect caused by CCAR2 deficiency.
To get a more in-depth picture of the regulation of 
Chk2 activity by CCAR2, we analysed the association 
between Chk2 and KAP1 in CCAR2+/+ and CCAR2-
/- cells. Interestingly, whereas in CCAR2-WT cells the 
binding between Chk2 and KAP1 decreased upon DNA 
damage, possibly because Chk2 releases its substrates 
after phosphorylation as previously reported [8, 29, 30], 
in CCAR2-KO cells this binding increased (Figure 5D), 
concordant with a defective Chk2 activity towards KAP1. 
Moreover, since Chk2 homodimerization is required for its 
autophosphorylation and activity, we determined whether 
the catalytic defect observed in CCAR2 deficient cells 
could be ascribed to impaired homodimerization. For 
this, CCAR2+/+ and CCAR2-/- cells were transfected 
with vectors encoding HA-Chk2 and FLAG-Chk2, 
ectopic proteins were immunoprecipitated with the anti-
HA antibody and immunoblotted with anti-FLAG as 
previously reported [31]. As shown in Figure 5E, Chk2 
homodimerization was induced in response to DNA 
damage, especially at 3h of treatment, in CCAR2-WT, but 
not in CCAR2-KO cells. Altogether, these results suggest 
that CCAR2 might affect Chk2 autophosphorylation 
and activity towards its substrates by regulating its 
homodimerization and interaction with target proteins. 
Collectively our data indicate that, in response to 
DNA damage, CCAR2 favours Chk2 dimerization and 
activation, leading to KAP1 phosphorylation, which is 
required for heterochromatic DNA repair by regulation 
of chromatin relaxation (Figure 6). These findings are 
consistent with the preferential repair of heterochromatic 
DNA breaks by homologous recombination [32], in which 
CCAR2 is involved [33], and suggest a new mechanism of 
Chk2 activity regulation. 
DISCUSSION
Here, we describe a novel function for CCAR2 
implicated in the repair of DNA lesions in heterochromatic 
regions of the genome. Notably, these events are not 
mediated by CCAR2 dependent inhibition of SIRT1, the 
main CCAR2 target in the DNA damage response [34, 35], 
but, instead, they seem to be dependent on defective Chk2 
activity regulation. 
To evaluate DNA repair, we analyzed the formation 
and clearance of γH2AX and 53BP1 foci, two well-known 
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Figure 5: Chk2 transfection restores DNA repair in CCAR2 negative cells. A. Chk2 was silenced in U2OS CCAR2+/+ and 
CCAR2-/- cells and the percentage of cells with >60 foci (left) and the average number of foci in the remaining cells (right) were evaluated 
after etoposide treatment. B. Example of 53BP1 staining in etoposide treated CCAR2-/- cells transfected with mock or Chk2 encoding 
vectors. C. Percentage of cells with more than 60 foci (left) and average number of foci in the remaining cells (right) in CCAR2-/- cells 
transfected with mock, Chk2WT or Chk2KD vectors 24h upon etoposide exposure. Charts represent the mean and standard deviation of three 
independent experiments, with significant p-values indicated. D. Co-IP between Chk2 and KAP1 before and after DNA damage in CCAR2+/+ 
and CCAR2-/- cells. PC: pre-cleared negative control. E. FLAG-Chk2 and HA-Chk2 encoding vectors were transfected in CCAR2+/+ and 
CCAR2-/- cells. Homodimerization was evaluated by analysis of FLAG-tagged Chk2 in HA-tagged Chk2 immunocomplexes. Relative 
fold indicates the densitometric quantification of FLAG-Chk2 co-immunoprecipitated with HA Chk2; data were normalized to CCAR2+/+ 
untreated sample.
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markers of DSBs [25], in U2OS and BJ-hTERT human 
cells. Particularly, 24h after damage induction by both 
etoposide and IR, we observed the presence of cells with 
un-repaired DNA lesions and therefore a high number of 
γH2AX and 53BP1 positive foci. Thus this phenomenon is 
irrespective of the source of DSBs since etoposide mainly 
produces breaks during S and G2 phases of the cell cycle, 
whereas IR can damage cells in all cell cycle phases. 
These defects in DNA repair are present in highly cycling 
U2OS cells and slowly growing BJ-hTERT cells and do 
not derive from alterations of cell cycle progression since 
CCAR2 depletion does not affect cell cycle distribution 
of untreated cells nor checkpoint activation after damage. 
Moreover, staining with cyclin B1 (a marker of G2 phase 
cells) demonstrated that cells with a high number of foci 
are not all in the same phase of the cell cycle. Thus, we 
hypothesize that cells with a high amount of foci (>60), 
24h after damaging treatment, are unable to repair DNA 
Figure 6: Graphical representation of the CCAR2 role in Chk2 activation and DNA repair. In unstressed cells Chk2 kinase 
exists as inactive monomer. Upon DNA damage, CCAR2 contributes to Chk2 homodimerization and activation by autophosphorylation, 
which induces KAP1 phosphorylation on S473, thus increasing DSBs repair, possibly by induction of chromatin relaxation.
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breaks and could be committed to death.
As previous reports suggest that CCAR2 could be 
implicated in the regulation of chromatin remodelling 
through its interaction with SIRT1, HDAC3, SUV39H1 
and KAP1 [2, 3, 9, 10, 15], we hypothesized that CCAR2 
could be necessary for the repair of those DNA breaks 
which require chromatin modification. It is now well 
established that DSBs which are repaired at late time 
points after DNA damage induction and necessitate 
chromatin relaxation, are those localized in the more 
compact heterochromatic regions of the genome [11, 
12]. Thus, we investigated if the DNA repair deficiency 
detectable in CCAR2 negative cells could be ascribed to 
defective heterochromatic repair. Indeed, we found that 
depletion of HP1β, which induces chromatin relaxation 
[19], can abrogate the defect caused by CCAR2 absence. 
Moreover, in CCAR2-/- cells, retaining an elevated 
number of foci, 53BP1 strongly interacts with H3K9me3. 
Conversely, when we induced DNA damages in only 
euchromatic regions, using the AID-DIvA cells [27], no 
defects were detected in CCAR2 depleted cells, further 
confirming that CCAR2 is involved in the repair of 
heterochromatic DNA lesions.
These findings are consistent with the fact that 
heterochromatic DNA breaks are preferentially repaired 
through homologous recombination [11, 36, 37] and 
CCAR2 involvement in this mechanism has already been 
reported [33]. 
Curiously, these events seem to be independent of 
SIRT1, even if this deacetylase was previoulsy reported 
to be involved in both conservative and non conservative 
DNA repair pathways [38, 39], but involve the Chk2 
kinase activity towards KAP1. It’s well established 
that CCAR2 interacts with the kinase Chk2 [7], which 
has among its targets also the transcriptional repressor 
KAP1 [18, 19]. In particular, Chk2 phosphorylates KAP1 
on Ser473 decreasing the interaction between KAP1 
and HP1 proteins: this post translational modification 
promotes HP1β mobilization and the reorganization of 
chromatin structure favoring the repair of DNA breaks 
inside heterochromatin [18, 19]. However, controversial 
data about the role of KAP1-S473 phosphorylation in the 
DNA damage response exist. Indeed other groups reported 
that this modification does not affect the binding of KAP1 
with HP1 proteins [21, 40], but that it is involved in the 
maintenance of G2/M checkpoint upon IR [41]. Our data 
demonstrating the decrease of KAP1-HP1α interaction 
upon etoposide exposure in CCAR2+/+ cells and the 
induction of this association in CCAR2-/- cells, where the 
phosphorylation of S473 is reduced, further confirm the 
role of this modification in the regulation of KAP1-HP1 
proteins association which finally impacts on chromatin 
structure leading to increased accessibility for repair 
factors. These data are in accordance with those previously 
reported [21] demonstrating that disruption of KAP1-HP1 
association facilitates γH2AX foci resolution. In contrast 
we did not find any role of KAP1-S473 phosphorylation 
in G2/M checkpoint activation and sustainment, since both 
CCAR2+/+ and CCAR2-/- cells did not display significant 
differences in cell cycle checkpoint activation. However 
it is possible that the reduction of S473 observed in 
CCAR2-/- cells could not be sufficient to affect cell cycle 
checkpoints.
Curiously we found that, although the priming 
phosphorylation of Chk2 on T68 by ATM is not affected 
by CCAR2, the dimerization and the autophosphorylation 
on T387 of Chk2, essential for a full activity of Chk2 on 
its substrates [8], are reduced in CCAR2 ablated cells. 
This reduction of Chk2 activation finally leads to defective 
phosphorylation of KAP1 on S473 that can prevent 
chromatin relaxation and DNA repair. Of note, we found 
as previously reported [21] that KAP1 phosphorylated 
on S473 does not accumulate in DNA damage induced 
foci (data not shown), as expected because of its role in 
the induction of global chromatin relaxation upon DNA 
damage. Beside this, our results suggest that CCAR2 
could be involved in the regulation of the interaction 
between Chk2 and its substrates. Indeed, in CCAR2-WT 
cells, Chk2-KAP1 association decreases in response to 
DNA damage, whereas it is induced in CCAR2 negative 
cells. This phenomenon could be explained with the fact 
that Chk2 releases its substrates after phosphorylation 
[8, 29, 30], but maintains the interactions in the case of 
defective catalytic activity.
As a consequence of these observations we 
hypothesize that CCAR2 could exerts a direct role in Chk2 
activation, possibly favoring the proper conformational 
changes necessary for Chk2 dimerization and auto-
phosphorylation; nevertheless, other proteins could be 
involved in this molecular mechanism, contributing to 
finely regulate Chk2 activities during the DNA damage 
response. Of note, CCAR2 is the first protein described 
to affect Chk2 dimerization without impairing the ATM 
activity on Chk2, even if our experiments revealed 
that ATM could play a role in regulating Chk2 activity 
through CCAR2. Indeed, in the analysis of Chk2 auto-
phosphorylation, we found that overexpression of CCAR2 
mutated in the ATM target site (CCAR2T454A [2]) has a 
minor effect compared to CCAR2WT overexpression; 
moreover, when we evaluated KAP1-phospho-S473 
in U2OS-CCAR2 negative cells re-complemented 
with CCAR2WT or CCAR2T454A vectors, we found that 
CCAR2T454A overexpression rescued the phosphorylation 
defect of CCAR2-/- cells to a less extent than CCAR2WT 
overexpression.
However, since we found that Chk2 pro-apoptotic 
activity is not affected by the presence of CCAR2, we do 
not know whether CCAR2 regulates in the same manner 
also Chk2 activity towards targets different from KAP1. 
Indeed it is possible that CCAR2 could be involved in the 
regulation of specific, but not all, Chk2 activities. 
Collectively our data indicate that, in response 
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to DNA damage, CCAR2 is required for the proper 
dimerization and activation of Chk2 which finally 
leads to Chk2-dependent KAP1 phosphorylation and 
heterochromatic DNA repair, possibly by the regulation 
of chromatin relaxation (Figure 6). These data illustrate 
a new mechanism of Chk2 activity regulation and further 
confirm the role of CCAR2 in the DDR, suggesting 
for this protein an important role in genomic stability 
maintenance, given that the majority of mutations and 
chromosomal aberrations of cancer cells reside in the 
heterochromatic regions of the genome [42]; for this, our 
studies may also support the controversial hypothesis that 
CCAR2 could act as a tumor suppressor gene [43]. 
 
MATERIALS AND METHODS
CCAR2-/- cells production by CRISPR/Cas9 
system
To generate CCAR2-/- cell lines we used the 
CRISPR/Cas9 system [22]. For this, a 20nt sequence 
(5’-GGAGTGAGGTGGACCCGGTA -3’) complementary 
to exon 8 of genomic CCAR2 and verified by 
computational analyses to exclude OFF-target effects 
[44], was cloned into the gRNA_Cloning vector (Addgene 
plasmid 41824) according to the reported protocol [22]. 
The CCAR2-gRNA and human codon optimised Cas9 
encoding vectors (Addgene 41815) were transfected in 
U2OS cells and 72h later analyzed by IF to determine the 
percentage of CCAR2-negative cells, and then subcloned. 
Clones were first screened by IF and WB and then the 
presence of indel was verified by sequencing. In this study 
we also used a BJ-hTERT clone knocked out for CCAR2 
generated with the same system.
Cell lines and treatments
Human osteosarcoma U2OS cells and U2OS AID-
DIvA cells (a kind gift of Dr. G. Legube) were cultured 
as reported [7, 27]. BJ-hTERT human fibroblast cells 
were grown in DMEM/Medium199 (4:1) with 10% of 
fetal bovine serum and 10µg/ml Hygromycin B. The 
Chk2 inhibitor VRX0466617 was kindly provided by Dr 
Minmin Yang (Pharmablock) and added to cells at 100 µM 
1h before treatments. Etoposide (TEVA) was used at 20 
µM. FACS analyses were performed as described [26]. 
Irradiations were performed in an IBL437CO instrument 
equipped with a 137Ce source emitting a dose of 8 Gy/min.
Expression vectors, siRNAs and tranfections
Vectors encoding CCAR2WT, CCAR2T454A, HA-Chk2 
and FLAG-Chk2 were previously described [2, 31]. HP1α 
c-DNA was obtained from Addgene (plasmid 17652) 
and then cloned in the pcDNA3-FLAG vector. siRNAs 
against CCAR2 and SIRT1 were ON-TARGET plus 
SMART pool (Thermo Scientific Dharmacon), whereas 
those against HP1β were FlexiTube siRNA (Qiagen). 
Lipofectamine 2000 (Invitrogen) and Lipofectamine 
RNAiMAX (Invitrogen) were used for plasmids and 
siRNAs transfections, respectively, according to the 
manufacturer’s instructions.
Western blots, antibodies and 
immunoprecipitations
The NuPAGE system (Life Technologies) was used 
for western blot analyses and densitometric evaluations 
were performed with the ImageQuant 5.2 software 
(Molecular Dynamics). Quantification of protein levels 
were normalized to loading control and for phosphorylated 
proteins to total protein. Antibodies used in this study 
were: CCAR2 (Bethyl Laboratories or Cell Signaling 
Technology); phospho-Chk2-T68, phospho-Chk2-T387, 
Cleaved Caspase-9, KAP1, phospho-KAP1-S824, SIRT1, 
phospho-p53-S20 (Cell Signaling Technology); phospho-
KAP1 S473 (Biolegend); 53BP1 (Novus), γH2AX and 
H3K9me3 (Upstate); FLAG (clone M2) and β-Actin 
(Sigma); HA (clone 12CA5, Roche); HP1β (Epigentek); 
phospho-ATM-S1981 (R&D); ATM (Epitomics); p53 
(Santa Cruz, DO-7). Chk2 antibody (clone 44D4/21) was 
previously described [45] and used for IP. For western 
blot Chk2 antibody from MBL Intl Corp (DCS-270 and 
DCS-273) was used. IP experiments were carried out as 
described [46] except for the interaction between HP1α 
and KAP1 that was assayed after cell lysates sonication 
and co-immunoprecipitations of 53BP1 and H3K9me3 
that were performed as reported [20]. 
Immunofluorescence and γH2AX or 53BP1 foci 
enumeration
Cells grown on glass coverslips were fixed with 
paraformaldehyde, permeabilized with 0.2% Triton X-100, 
blocked in PBS, 5% BSA, 0.1% Tween 20, stained with 
anti γH2AX (Upstate) or anti-53BP1 antibodies (Novus 
Biologicals, 100-304) and counterstained with DAPI. For 
cyclin B1 staining cells were permeabilized with 0.5% 
Triton, blocked in 3% BSA and incubated with cyclin 
B1 (BD Pharmingen) and 53BP1 antibodies. Coverslips 
were scored by fluorescence microscopy and digital image 
acquisition on a Nikon Eclipse E1000 equipped with a DS-
U3 CCD camera. 
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γH2AX and 53BP1 foci were stained by 
immunofluorescence in CCAR2+/+ and CCAR2-/- cells 
untreated or treated for 1h with etoposide and then released 
in drug free medium for the indicated time points. Foci 
were scored on >100 nuclei by fluorescence microscopy 
using a 100X magnification objective by two independent 
operators. Standard deviations were calculated on the 
mean values of at least three independent experiments. P 
values were determined by t-student test.
G1/S and G2/M transition evaluation
To evaluate G1/S transition, DNA replicating cells 
were detected with the Click-iT EdU assay kit (Life 
Technologies). Cells were treated with etoposide for 1h, 
released in EdU containing medium for 4h and stained 
according to manufacturer’s instruction. For G2/M 
transition, etoposide treated cells were released in medium 
containing 100ng/ml of nocodazole to trap checkpoint 
defective cells. Mitotic cells were stained with an Alexa 
Fluor-488 conjugated anti phospho-histone-H3 (S10) 
antibody (Cell Signaling).
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